億帆醫藥(002019.SZ):Bioton生產的人胰島素注射液產品中的3個產品均以A類排名擬中選集採
格隆匯11月26日丨億帆醫藥(002019.SZ)公佈,2021年11月26日,公司全資子公司合肥億帆生物製藥有限公司(“億帆製藥”)參加了國家組織藥品聯合採購辦公室(“聯合採購辦公室”)組織的第六批全國藥品集中採購(胰島素專項)。公司持有31.65%股權的參股公司Bioton S.A.(“佰通公司”,公司為其第一大股東)生產的人胰島素注射液產品中此次申報的3個產品(國內分包裝產品)均以A類排名擬中選本次集中採購,公示期為2021年11月27日-2021年11月29日。現將相關情況公吿如下:

2018年3月,公司取得佰通公司人胰島素注射液系列產品除波蘭市場以外的全球代理權,並於2020年開始負責國內市場的銷售。2020年2月,億帆製藥開始獲得進口藥品人胰島素注射液系列產品國內分包裝批件。2020年度,人胰島素注射液系列產品國內銷售收入為5992.4萬元(自2020年5月起),佔公司2020年度銷售收入的比重為1.11%。
此次集中採購是國家組織的第六批藥品集中帶量採購,採購週期中,醫療機構將優先使用本次藥品集中採購中選藥品,並確保完成約定採購量。若公司後續簽訂採購合同並實施後,將有利於進一步擴大中選產品在中國境內的銷售,提高中選產品的市場的佔有率,提升公司的品牌影響力,對公司的未來經營業績產生積極的影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.